BioSpace News Archive

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce the presentation of two posters at the San Antonio Breast Cancer Symposium, in San Antonio, Texas, United States, between 06-10 December 2022.

Galera Therapeutics, Inc. (Nasdaq: GRTX) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for avasopasem for radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer (HNC) undergoing standard-of-care treatment.

IN8bio, Inc. today announced updated results from the ongoing Phase 1 trial evaluating INB-100, an allogeneic, gamma-delta T cell therapy, in patients with hematologic malignancies undergoing haploidentical stem cell transplantation (HSCT).

PolyPid Ltd. today announced that a Type D meeting has been scheduled for January 2023 with the U.S. Food and Drug Administration (FDA) to discuss the results of SHIELD I Phase 3 study and regulatory requirements to support the indication of D-PLEX100 for the prevention of abdominal colorectal surgical site infections (SSIs).

Rectify Pharmaceuticals, Inc. announced the publication of an article highlighting the therapeutic potential of the ABC transporter class in Trends in Molecular Medicine.

GlycoMimetics, Inc. today announced results from two investigator-sponsored trials studying uproleselan in patients with acute myeloid leukemia (AML).

First Wave BioPharma, Inc. announced today the company will participate in BIO Partnering @ JPM being held January 9-12, 2023 in San Francisco.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the company has been included on the Dow Jones Sustainability World Index (DJSI World) for the fourth consecutive year and on the Dow Jones Sustainability North America Index (DJSI North America) for the third year.

Inventiva announced the receipt of the €25 million payment under the first tranche of the unsecured loan agreement executed with the European Investment Bank on May 16, 2022 with a maturity date of December 2026.

IRRAS announced that it received regulatory clearance from the United States Food, Drug, and Administration to active all of the functionality on the next generation control unit for its flagship product, IRRAflow, the world’s first and only active fluid exchange system.